English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

According to current US Food and Drug Administration ( FDA ) and European Medicines Agency ( EMA ) guidance documents, physiologically based pharmacokinetic ( PBPK ) modeling is a powerful tool to explore and quantitatively predict drug‐drug interactions ( DDI s) and may offer an alternative to dedicated clinical trials. This study provides whole‐body  PBPK  models of rifampicin, itraconazole, clarithromycin, midazolam, alfentanil, and digoxin within the Open Systems Pharmacology ( OSP ) Suite. All models were built independently, coupled using reported interaction parameters, and mutually evaluated to verify their predictive performance by simulating published clinical  DDI  studies. In total, 112 studies were used for model development and 57 studies for  DDI  prediction. 93% of the predicted area under the plasma concentration‐time curve ( AUC ) ratios and 94% of the peak plasma concentration (C max ) ratios are within twofold of the observed values. This study lays a cornerstone for the qualification of the  OSP  platform with regard to reliable PBPK predictions of enzyme‐mediated and transporter‐mediated  DDI s during model‐informed drug development. All presented models are provided open‐source and transparently documented.

PBPK Models for CYP3A4 and P‐gp DDI Prediction: A Modeling Network of Rifampicin, Itraconazole, Clarithromycin, Midazolam, Alfentanil, and Digoxin